Abstract: Nonnucleoside reverse transcriptase inhibitor-associated TDRMs were detected in 3.3% (44/1,306) of patients (
L100I,
K101E/P,
K103N/S,
V179F,
Y188H/L/M,
Y181I/C, and
G190A/E/S) and TDRMs to
protease inhibitors were detected in 2.3% (30/1,306) of patients (
M46L,
I50V,
I54V,
Q58E,
L76V,
V82A/C/L/T,
N83D,
I84V, and
L90M